HLS Therapeutics Inc. (HLS) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Hls Therapeutics, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.772 Good morning and welcome to the second quarter fiscal 2026 financial results conference 00:00:04.772 -- 00:00:09.474 call for HLS Therapeutics. At this point, I would like to turn the call over to David 00:00:09.474 -- 00:00:12.815 Mason, Investor Relations, for the introductory remarks. 00:00:12.815 -- 00:00:15.076 Please go ahead. 00:00:15.076 -- 00:00:18.677 Good morning, everyone, and thank you for joining us today. 00:00:18.677 -- 00:00:23.818 With me on the call are Craig Millian, Chief Executive Officer, John 00:00:23.818 -- 00:00:30.537 Hanna, Chief Financial Officer, and Brian Walsh, Chief Operating Officer. 00:00:30.537 -- 00:00:35.940 Earlier this morning, we issued a news release announcing our financial results 00:00:35.940 -- 00:00:40.902 for the three and six months ended June 30, 2026. 00:00:40.902 -- 00:00:46.185 This news release, along with our MD&A and financial statements, is available 00:00:46.185 -- 00:00:50.007 on our website and on CDAR+. 00:00:50.007 -- 00:00:55.670 Please note that slides accompanying today's call can be viewed via the webcast, 00:00:55.670 -- 00:01:01.196 a link to which is available in our earnings press release and on our website 00:01:01.196 -- 00:01:03.796 on the events page. 00:01:04.057 -- 00:01:08.479 Certain matters discussed in today's conference call or answers that may be given to 00:01:08.479 -- 00:01:12.440 questions could constitute forward-looking statements. 00:01:12.440 -- 00:01:16.682 Actual results could differ materially from those anticipated. 00:01:16.682 -- 00:01:21.444 Risk factors that could affect results are detailed in the company's annual information 00:01:21.444 -- 00:01:25.605 form, which has been filed on CDAR+. 00:01:26.046 -- 00:01:30.989 During the call...